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Abstract
Background: Insulinemia and type 2 diabetes (T2D) have been associated with endometrial cancer risk in numerous 
observational studies. However, the causality of these associations is uncertain. Here we use a Mendelian randomization 
(MR) approach to assess whether insulinemia and T2D are causally associated with endometrial cancer.
Methods: We used single nucleotide polymorphisms (SNPs) associated with T2D (49 variants), fasting glucose (36 variants), 
fasting insulin (18 variants), early insulin secretion (17 variants), and body mass index (BMI) (32 variants) as instrumental 
variables in MR analyses. We calculated MR estimates for each risk factor with endometrial cancer using an inverse-variance 
weighted method with SNP-endometrial cancer associations from 1287 case patients and 8273 control participants.
Results: Genetically predicted higher fasting insulin levels were associated with greater risk of endometrial cancer (odds 
ratio [OR] per standard deviation = 2.34, 95% confidence internal [CI] = 1.06 to 5.14, P = .03). Consistently, genetically predicted 
higher 30-minute postchallenge insulin levels were also associated with endometrial cancer risk (OR = 1.40, 95% CI = 1.12 to 
1.76, P = .003). We observed no associations between genetic risk of type 2 diabetes (OR = 0.91, 95% CI = 0.79 to 1.04, P = .16) or 
higher fasting glucose (OR = 1.00, 95% CI = 0.67 to 1.50, P = .99) and endometrial cancer. In contrast, endometrial cancer risk 
was higher in individuals with genetically predicted higher BMI (OR = 3.86, 95% CI = 2.24 to 6.64, P = 1.2x10-6).
Conclusion: This study provides evidence to support a causal association of higher insulin levels, independently of BMI, 
with endometrial cancer risk.
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Metabolic diseases such as type 2 diabetes (T2D) are an estab-
lished and growing worldwide concern with important public 
health implications (1,2). In particular, insulin concentrations 
and T2D have been associated with higher incidence and mortal-
ity from numerous cancers in observational studies (3,4). Insulin 
resistance and elevated C-peptide, a marker of insulin release, 
confer a higher risk of endometrial cancer (5,6). Furthermore, a 
meta-analysis of 16 studies showed that women with diabetes 
had a greater-than-two-fold higher endometrial cancer risk (7). 
However, insulin resistance, T2D, and endometrial cancer share 
common risk factors, such as higher body mass index (BMI), 
which may confound observational epidemiological studies (8). 
Therefore, it is uncertain if the associations between hyperinsu-
linemia and T2D with endometrial cancer are causal.
Where confounding is suspected in epidemiological stud-
ies and a randomized controlled trial is difficult to implement, 
Mendelian randomization provides a promising alternative (9). 
Using the example of fasting insulin, this method is akin to a 
“genetically randomized controlled trial” where, under Mendel’s 
law of independent assortment, individuals are randomly 
assigned to varying levels of insulin, independently of confound-
ing variables. This approach is dependent on three assumptions 
of genetic variants used as instrumental variables: first, that the 
genetic variants are associated with the risk factor (ie, insulin); 
secondly, that the variants are not associated with other con-
founders; and thirdly, that the variants are independent of the 
outcome given the risk factor and confounders (9). Using this 
design, a genetically conferred elevation in insulinemia should 
result in a higher risk of endometrial cancer only if insulinemia 
is truly on the causal pathway for this disease.
Recently, a number of variants have been identified to be 
associated with fasting and postchallenge insulin levels (10). 
Here we implement a Mendelian randomization approach to test 
whether hyperinsulinemia, T2D, and related traits are causally 
related to endometrial cancer. Using data from genome-wide 
association studies (GWAS) of endometrial cancer, we examine 
the association of single nucleotide polymorphisms (SNPs) for 
fasting insulin (FI), postchallenge insulin, fasting glucose (FG), 
BMI, and T2D with endometrial cancer.
Methods
Instrumental Variable Definition
We utilized genetic variants associated with each risk factor (FI, 
FG, postchallenge insulin, T2D, and BMI). Where available, we 
included all variants associated with FI (11), T2D (12–15), FG (11), 
and BMI (16) at genome-wide statistical significance thresholds 
(P  <  5 x 10–8) in previously published large-scale genome-wide 
meta-analyses in individuals of European ancestry. For postch-
allenge insulin secretion, where discovery sample sizes are 
smaller (17), variants from a genetic score shown to be strongly 
associated with insulin secretion (10) were included. In recently 
published large-scale meta-analyses (17), two (of 19)  variants 
previously included in the insulin secretion score (near DGKB 
and TFB1M) had an opposite direction of effect to that expected 
(albeit with statistically nonsignificant associations) and, as 
such, were excluded from analyses as detailed in Supplementary 
Table  1 (available online). As the effects of FTO variants on FI 
and T2D appear entirely mediated through higher BMI (11,18), 
variants from this locus were excluded from the FI- and T2D-
associated SNPs to minimize potential confounding by BMI. In 
total, 18 FI-associated variants, 49 T2D-associated variants, 36 
FG-associated variants, 32 BMI-associated variants, and 17 vari-
ants associated with early postchallenge insulin secretion (10) 
were included in analyses (Supplementary Table  1, available 
online).
Summary Statistic Mendelian Randomization
For each risk factor we estimated “SNP-risk factor” and “SNP-
endometrial cancer” associations (and their standard errors) to 
calculate individual SNP estimates of each “risk factor–endo-
metrial cancer” association, which were then combined using 
an inverse-variance weighted approach (19). Using this method, 
the association of each genetically predicted risk factor with 
endometrial cancer was estimated as a mean of individual SNP 
effects on endometrial cancer with each variant weighted by 
its effect on the relevant exposure (ie, FI). As one of the SNPs 
associated with postchallenge insulin secretion (rs7903146) was 
also associated with fasting insulin, we performed a sensitivity 
analysis excluding this variant from the postchallenge insulin 
secretion-associated SNPs. The effect sizes for the association 
of genetic variants and their respective traits were taken from 
replication-only effect size estimates from previously published 
large GWAS for FI, FG, BMI, and the presence of T2D (11,15,16) to 
obtain the most accurate estimates available. As variants asso-
ciated with insulin secretion were identified through a range of 
sources (10), they were weighted according to the magnitude of 
their association (in discovery analyses) with 30-minute insulin 
in recent meta-analyses (17). All weighting factors are shown in 
Supplementary Table 1 (available online).
We examined the potential for confounding by investigating 
the association of unweighted genetic scores comprising the above 
variants with a range of potential confounders in the Fenland 
study (20) and with 30-minute insulin in the Ely study (21). These 
included age, age at menarche and menopause, BMI, FG, FI, 30-min-
ute insulin, as well as with self-reported physical activity levels (22) 
and total energy intake, by linear regression. We also investigated 
the association of genetic scores with level of education (whether 
the highest level of education was up to a General Certificate of 
Secondary Education [GCSE] or whether A-level or degree level 
qualifications were obtained) as a proxy for socioeconomic status, 
by logistic regression. We additionally tested the association of the 
genetic scores with smoking status (never vs ever).
Endometrial Cancer Associations
The associations of the selected variants with endometrial cancer 
were taken from an updated GWAS of endometrial cancer (23). 
All case patients were of endometroid histology and were derived 
from the Australian National Endometrial Cancer Study (ANECS; 
n = 606 case patients) or the Studies of Epidemiology and Risk fac-
tors in Cancer Heredity study (SEARCH; n = 681 case patients) (23). 
UK control participants (n = 5190) were derived from the Wellcome 
Trust Case Control Consortium 2 (WTCCC2) (24), and Australian 
control participants were from the parents of the twins in the 
Brisbane Adolescent Twin Study (n = 1846) (25) and from the Hunter 
Community Study (n  =  1237) (26). All individuals provided writ-
ten informed consent, and respective institutional review board 
approval was granted. Further details on each study are provided 
in the Supplementary Material (available online). In total, the endo-
metrial cancer study comprised 1287 case patients and 8273 con-
trol participants. Studies from the UK and Australia were analyzed 
separately and combined using a fixed-effect inverse-variance 
weighted meta-analysis, with the Australian analysis adjusted for 
the first two principal components and the UK analysis adjusted 
for the first three principal components to account for latent popu-
lation stratification.
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Genotyping for the endometrial cancer case patients 
was carried out using the Human 610K array on the Illumina 
Infinium platform. Variants not meeting the following quality 
control thresholds were excluded: 1) call rate of 95% or greater 
with minor allele frequency of 0.05 or greater or call rate of 99% 
or greater with minor allele frequency under 0.05; 2)  Hardy-
Weinberg equilibrium P value of greater than 10–12 for case 
patients or P value of greater than 10–7 for control participants. 
Genotype imputation using HapMap 2 CEU data (27) as the refer-
ence panel was performed using MACH software (28). Imputed 
SNPs with an imputation R2 of less than 0.6 were excluded.
Scaling of Results for Each Genetically Predicted 
Risk Factor
For continuous variables, the results of the weighted method are 
scaled per standard deviation (SD) of log-FI, FG, BMI, and per SD 
of log 30-minute insulin. Standard deviations were derived from 
the population-based Fenland or Ely studies (20,21) and shown 
in Table 1. Therefore, for continuous exposures, the effect sizes 
represent the odds ratio of endometrial cancer per genetically 
predicted SD increase in the exposure. When T2D is the expo-
sure, the effect size represents the odds ratio of endometrial 
cancer per genetically predicted increase of one in the log-odds 
of T2D.
Individual variants were examined for association with 
endometrial cancer using Bonferroni-corrected two-sided P val-
ues (eg, for T2D, α = 0.05/49). Tests were otherwise considered 
statistically significant if the two-sided P value was under .05. 
All analyses were performed using Stata version 12.0 (StataCorp, 
College Station, TX) or as otherwise indicated.
Results
We observed an association of variants associated with higher 
fasting insulin with higher risk of endometrial cancer (odds ratio 
[OR] per genetically predicted SD of log-FI = 2.34, 95% confidence 
interval [CI] = 1.06 to 5.14, P =  .03) (Table 1). We found a direc-
tionally consistent association of genetically predicted higher 
postchallenge insulin levels with a higher risk of endometrial 
cancer (OR = 1.40, 95% CI = 1.12 to 1.76, P =  .003). After exclu-
sion of the rs7903146 variant, which was also associated with 
FI, from the postchallenge insulin-associated secretion SNPs the 
result remained statistically significant (OR = 1.32, 95% CI = 1.05 
to 1.67, P = .02). No association was found for T2D (OR = 0.91, 95% 
CI = 0.79 to 1.04, P = .16) or FG (OR = 1.00, 95% CI = 0.67 to 1.50, 
P  =  .99) with endometrial cancer (Table  1). We found a more-
than-three-fold higher endometrial cancer risk per genetically 
predicted SD increase in BMI (OR = 3.86, 95% CI = 2.24 to 6.64, 
P = 1.2x10-6) (Table 1).
For the fasting insulin, postchallenge insulin, and BMI-
associated variants, we evaluated the potential for individ-
ual pleiotropic outlier SNPs to underlie associations, but we 
observed no clear outliers (Supplementary Figure 1, A-C, avail-
able online). Three individual variants reached Bonferroni-
corrected statistical significance thresholds for association 
with endometrial cancer (Supplementary Table  1, available 
online). The BMI-increasing allele at FTO was associated with 
higher risk of endometrial cancer (OR = 1.16, 95% CI = 1.07 to 
1.27, P = 5.6 × 10–4), which may reflect the larger effect size of FTO 
variants on BMI than other variants (Supplementary Figure 1C, 
available online). Genetically predicted BMI remained associ-
ated with higher risk of endometrial cancer after excluding the 
FTO variant (OR = 3.19, 95% CI = 1.70 to 6.03, P = 3.2 × 10–4). The 
T2D risk-increasing allele of HNF1B variant rs11651052 (A) was 
protective against endometrial cancer (OR = 0.82, 95% CI = 0.76 
to 0.89, P  =  3.7 × 10–6), while the FG-raising G-allele of ADRA2A 
variant rs10885122 (OR = 1.32, 95% CI = 1.13 to 1.54, P = 3.6 × 10–4) 
was associated with a higher endometrial cancer risk. Removing 
these variants did not change the associations of genetically 
predicted fasting glucose or T2D risk with endometrial cancer 
(Table 2).
To further investigate the potential for pleiotropy, and the 
extent to which our Mendelian randomization was “rand-
omized,” we investigated the association of genetic scores com-
prising risk factor–associated SNPs with a range of potential 
confounders. We found no compelling evidence for the asso-
ciations we report being driven by these confounders (Figures 
1–3; Supplementary Figures 2 and 3, available online). In most 
instances, genetic scores were associated with their relevant 
risk factors, but not with other traits. We did observe an associa-
tion of the BMI score with age at menarche (Figure 1) (29) and of 
the insulin secretion score with fasting glucose (Figure 3) (10). 
However, importantly, neither the fasting insulin (P  =  .63) nor 
the insulin secretion score (P  =  .32) were associated with BMI 
(Figures 2 and 3).
Discussion
The present study provides evidence for a causal association 
between insulinemia and endometrial cancer that is inde-
pendent of known confounding factors, including BMI. This is 
supported by two nonoverlapping sets of genetic variants asso-
ciated with fasting and postchallenge insulin. Interestingly, we 
did not observe a causal association for T2D, nor with fasting 
glucose, despite the strong and consistent association of T2D 
with endometrial cancer demonstrated in observational studies.
Table 1. Associations with endometrial cancer per genetically pre-
dicted SD increase of each risk factor
Risk factor SD
OR per geneti-
cally predicted SD 
(95% CI) P*
Body mass index, kg/m2 4.81 3.86 (2.24 to 6.64) 1.2x10-6
Fasting glucose, mmol/L 0.65 1.00 (0.67 to 1.50) .99
Fasting insulin, ln(pmol/L) 0.60 2.34 (1.06 to 5.14) .03
Early insulin secretion, ln(pmol/L) 0.58 1.40 (1.12 to 1.76) .003
Type 2 diabetes, log-odds 1 0.91 (0.79 to 1.04) .16
* Inverse-variance weighted model. All statistical tests were two-sided. 
CI = confidence interval; OR = odds ratio.
Table 2. Associations with endometrial cancer per genetically pre-
dicted SD of each risk factor from sensitivity analyses, excluding 
single nucleotide polymorphisms exceeding Bonferroni-corrected 
thresholds for association with endometrial cancer
Risk factor SD
OR per geneti-
cally predicted SD 
(95% CI) P*
Body mass index, kg/m2 4.81 3.20 (1.70 to 6.03) <.001
Fasting glucose, mmol/L 0.65 0.94 (0.62 to 1.41) .76
Type 2 diabetes, log-odds 1 0.97 (0.85 to 1.12) .71
* Inverse-variance weighted model. All statistical tests were two-sided. 
CI = confidence interval; OR = odds ratio.
 at U
niversity of Cam
bridge on Septem
ber 25, 2015
http://jnci.oxfordjournals.org/
D
ow
nloaded from
 
K. T. Nead et al. | 4 of 7
a
r
t
ic
le
a
r
t
ic
le
A limited number of epidemiological studies have directly 
examined the association between hyperinsulinemia and endo-
metrial cancer. Independently of BMI, a greater-than-two-fold 
higher risk of endometrial cancer has been demonstrated when 
comparing women in the highest quartile of FI to those in the 
lowest quartile (5), and a more-than-four-fold higher risk of endo-
metrial cancer has been observed among women in the highest 
compared with lowest quintile of C-peptide levels (6). An additional 
study examined insulin resistance using the homeostasis model 
assessment ratio (HOMA-IR) and found that, compared with the 
lowest quartile, women in the highest quartile had a two-fold 
higher risk of endometrial cancer even after adjustment for waist-
hip ratio (30). Finally, higher FI has been associated with increased 
endometrial cancer stage and faster disease progression (31).
Our findings that a genetically predicted increase in FI raises 
endometrial cancer risk, while a genetically predicted increase in 
postchallenge insulin levels (not associated with insulin resist-
ance (10) or with FI [Figure 3]) also raises endometrial cancer risk, 
jointly support a causal role for hyperinsulinemia in the etiology 
of endometrial cancer. Hyperinsulinemia is a leading hypoth-
esis for the epidemiological association of T2D and endome-
trial cancer (7), with multiple plausible mechanisms to explain 
this observation. First, insulin decreases levels of sex hormone 
binding globulin (SHBG) by inhibiting its production in the liver 
(32). As SHBG typically binds estrogens and other sex hormones, 
lower levels of SHBG result in an elevation of bioavailable estro-
gens (33,34). Consequently, postmenopausal diabetic women 
have been observed to have higher levels of urinary estrogens 
as compared with postmenopausal nondiabetic women, inde-
pendent of body weight (35). As with the peripheral conversion 
of androgens to free estrogens when excess adipose tissue is pre-
sent, elevated estrogens secondary to hyperinsulinemia increase 
endometrial cell proliferation and decrease apoptosis, resulting 
in an increased endometrial cancer risk (36). Accordingly, there 
is some evidence that genetic variants that have been shown 
to increase SHBG levels are also associated with a lower risk of 
endometrial cancer (37). Secondly, hyperinsulinemia leads to 
decreased levels of insulin like growth factor binding protein, 
which results in elevated levels of free insulin-like growth factor 
1 (IGF-1) (7,38). IGF-1 receptors are present in endometrial tissue 
and have been shown to stimulate endometrial cell proliferation 
(39,40). Insulin itself may further contribute to endometrial cell 
proliferation, as it has been shown to act as an analogue of IGF-1 
in endometrial tissue (41). These direct actions of insulin may 
also contribute to the association of type 1 diabetes and endo-
metrial cancer (7), as mediated through the effects of exogenous 
insulin administration (42). Recent reports on individuals carry-
ing rare loss-of-function PTEN variants with a predisposition to 
a range of cancers (including endometrial) despite lower insulin 
levels may appear in conflict with our results (43). However, PTEN 
is a negative regulator of insulin signaling, such that PTEN defi-
ciency results in increased insulin signaling (44).
The association between higher BMI and endometrial can-
cer is well established in epidemiological studies (45). Excess 
adipose tissue results in greater peripheral aromatization of 
circulating androgens to bioavailable estrogen. Elevated estro-
gen levels have been shown to increase endometrial cancer 
risk, as estrogens are capable of stimulating endometrial cell 
proliferation and inhibiting apoptosis (36). Additionally, even 
in the absence of elevations in circulating estrogens, obesity is 
Age
Age at menarche
Outcome
8994
2015
N
.59
5.0x10-4
P-value
0.00 (-0.00 to 0.01)
-0.02 (-0.04 to -0.01)
Beta (95% CI)
Age at menopause 1476 .680.00 (-0.01 to 0.02)
Body mass index 8918 3.32x10-220.03 (0.02 to 0.04)
Fasting glucose 8966 .170.00 (-0.00 to 0.01)
Fasting insulin 7564 .040.01 (0.00 to 0.01)
30-minute insulin 1291 .020.02 (0.00 to 0.04)
Physical activity levels 8982 .96-0.00 (-0.01 to 0.01)
Energy intake 8982 .96-0.00 (-0.01 to 0.01)
Level of education* 
(GCSE/A level-degree)
3274/3080 .780.00 (-0.01 to 0.02)
Smoker* (never/ever) 4763/4203 .710.00 (-0.01 to 0.01)
0-0.08 -0.06 -0.04 -0.02 0.02 0.04 0.06
Beta in standard deviations per risk-allele
Body mass index genetic score
*Note that level of education and smoker status were binary 
variables and effect sizes are thus log-odds ratios
Figure 1. Association of a genetic score of body mass index (BMI)–associated single nucleotide polymorphisms with BMI and a range of potential confounders in the 
Fenland study (20). Thirty-minute insulin was only available in the Ely study (21), so the sample size is smaller. Given 55 tests (α = 9.1x10-4), the score was associated 
with BMI and with age at menarche (29). Associations with quantitative traits were tested by linear regression and with binary traits by logistic regression. All statisti-
cal tests were two-sided.
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a risk factor for endometrial cancer through obesity-induced 
insulin resistance and the resultant higher insulin levels (46), 
as discussed above. It has been demonstrated that individual 
BMI-increasing variants, particularly in FTO, are associated with 
higher endometrial cancer risk (47,48). Here we extend these 
findings by using multiple BMI-associated variants, augmenting 
the evidence that the association between BMI and endometrial 
cancer is causal. In the current analysis, a genetically predicted 
SD increase in BMI (4.81 kg/m2) was associated with a 3.86-fold 
higher risk of endometrial cancer. This finding is consistent with 
estimates from a meta-analysis of conventional epidemiological 
studies (45) where a 5 kg/m2 increase in BMI was associated with 
a three-fold higher risk of endometrial cancer among individu-
als with a BMI above 28 kg/m2. As the risk of endometrial can-
cer has been shown to be positively associated with the mean 
BMI in a population (49), a causal association between BMI and 
endometrial cancer indicates a likely increased future burden of 
disease among progressively obese populations.
The current study did not demonstrate an association 
between the T2D variants and endometrial cancer. One pos-
sibility is that we were underpowered to detect a true statisti-
cally significant association. However, this study was adequately 
powered to detect an association with genetically predicted ele-
vations in FI, and the FI SNPs explained only around 1% of the 
variance in FI (11), while the T2D variants explained approxi-
mately 5% of the variance in T2D (15). Furthermore, the T2D 
point estimate in this study was less than one, whereas a meta-
analysis of epidemiological studies predicts a two-fold increased 
risk of endometrial cancer (7). While recent analyses highlight 
that loci associated with T2D have a diverse range of underlying 
mechanisms (50), the point estimate for the T2D variants may 
reflect that many of these SNPs are associated with lower insu-
lin secretion. Thus, our results suggest that the association of 
T2D with the risk of endometrial cancer is driven by the hyper-
insulinemia observed in T2D, rather than hyperglycemia per se.
A primary assumption of this analysis is that the selected 
genetic variants are indeed associated with the exposure being 
tested (9). Therefore, we only used variants associated with the 
relevant exposure at genome-wide significance from hypothe-
sis-free genome-wide meta-analyses. While this level of asso-
ciation was not available for variants associated with insulin 
secretion, we have previously demonstrated that this genetic 
score was strongly, and specifically, associated with higher 
postchallenge insulin levels (10).
A second assumption of this analysis is that variants are 
associated with endometrial cancer only through the exposure 
and are unconfounded by pleiotropy (9). We saw no convincing 
evidence of confounding in analyses investigating pleiotropy 
(Figures 1–3; Supplementary Figures 2 and 3, available online). 
While not possible to exclude confounding by unknown con-
founders, the use of multiple independent variants acting 
through different pathways decreases the likelihood of con-
founded instrumental variable associations (9,51). Importantly, 
we saw no association of either the fasting or postchallenge 
insulin scores with BMI (Figures 2 and 3).
As with any Mendelian randomization analysis, there are 
potential limitations to our findings, including the limited trait 
variance explained by genetic variants, thus restricting statisti-
cal power. This is particularly relevant for null findings, where 
wide confidence intervals leave uncertainty over the presence of 
Age
Age at menarche
Age at menopause
Body mass index
Fasting glucose
Fasting insulin
30-minute insulin
Physical activity levels
Energy intake
Level of education* 
(GCSE/A level-degree
8994
2015
1476
8918
8966
7564
1291
8982
8982
3274/3080
4763/4203
.99
.64
.99
.63
.08
4.76x10-08
.03
.96
.91
.6
.42
0.00 (-0.01 to 0.01)
-0.00 (-0.02 to 0.01)
-0.00 (-0.02 to 0.02)
0.00 (-0.01 to 0.01)
0.01 (-0.00 to 0.01)
0.02 (0.01 to 0.03)
0.02 (0.00 to 0.04)
0.00 (-0.01 to 0.01)
0.00 (-0.01 to 0.01)
0.00 (-0.01 to 0.02)
0.01 (-0.01 to 0.02)
0-0.08 -0.06 -0.04 -0.02 0.02 0.04 0.06
Beta in standard deviations per risk-allele
Fasting insulin genetic score
Outcome N P-valueBeta (95% CI)
*Note that level of education and smoker status were binary 
variables and effect sizes are thus log-odds ratios
Smoker* (never/ever)
Figure 2. Association of a genetic score of fasting insulin–associated single nucleotide polymorphisms with fasting insulin and a range of potential confounders in 
the Fenland study (20). Thirty-minute insulin was only available in the Ely study (21), so the sample size is smaller. Given 55 tests (α = 9.1x10-4), the score was only 
associated with fasting insulin. Associations with quantitative traits were tested by linear regression and with binary traits by logistic regression. All statistical tests 
were two-sided.
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a small causal effect. Thus, further genetic discovery efforts com-
bined with larger studies of disease outcomes will further improve 
the utility and precision of Mendelian randomization analyses.
In conclusion, this study provides evidence for a causal role of 
higher insulin levels in the etiology of endometrial cancer. These 
findings are consistent with proposed mechanisms for the asso-
ciation of the T2D phenotype with endometrial cancer. Given the 
epidemics of obesity and insulin resistance, these findings indi-
cate a growing importance of hyperinsulinemia on endometrial 
cancer incidence. The potential contribution of exogenous insu-
lin to endometrial cancer development remains unknown but 
warrants consideration. Future studies should examine whether 
hyperinsulinemia and exogenous insulin have a causal role in 
disease progression and whether better insulin control results in 
decreased incidence or improved outcomes in endometrial cancer.
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Age 8994 .26-0.00 (-0.01 to 0.00)
Age at menarche 2015 .71-0.00 (-0.02 to 0.01)
Age at menopause 1476 .63-0.00 (-0.02 to 0.01)
Body mass index 8918 .32-0.00 (-0.01 to 0.00)
Fasting glucose 8966 5.52x10-170.03 (0.03 to 0.04)
Fasting insulin 7564 .52-0.00 (-0.01 to 0.01)
30-minute insulin 1291 1.06x10-6-0.05 (-0.08 to -0.03)
Physical activity levels 8982 .51-0.00 (-0.01 to 0.00)
Energy intake 8982 .89-0.00 (-0.01 to 0.01)
Level of education* 
(GCSE/A level-degree
3274/3080 .52-0.01 (-0.03 to 0.01)
0-0.08 -0.06 -0.04 -0.02 0.02 0.04 0.06
Beta in standard deviations per risk-allele
Early insulin secretion genetic score
Outcome N P-valueBeta (95% CI)
*Note that level of education and smoker status were binary 
variables and effect sizes are thus log-odds ratios
4763/4203 .45-0.01 (-0.02 to 0.01)Smoker* (never/ever)
Figure 3. Association of a genetic score of insulin secretion–associated single nucleotide polymorphisms with early insulin secretion and a range of potential con-
founders in the Fenland study (20). Thirty-minute insulin was only available in the Ely study (21), so the sample size is smaller. Given 55 tests (α = 9.1x10-4), the score 
was only associated with early insulin secretion and with fasting glucose. Associations with quantitative traits were tested by linear regression and with binary traits 
by logistic regression. All statistical tests were two-sided.
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